Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Johnson & Johnson (JNJ)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
163.72+0.32 (+0.20%)
At close: 4:00PM EDT
163.50 -0.22 (-0.13%)
After hours: 07:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close163.40
Open163.06
Bid163.46 x 800
Ask163.94 x 800
Day's Range162.96 - 164.06
52 Week Range133.65 - 179.92
Volume4,304,467
Avg. Volume5,852,117
Market Cap431.14B
Beta (5Y Monthly)0.70
PE Ratio (TTM)28.92
EPS (TTM)5.66
Earnings DateOct 19, 2021
Forward Dividend & Yield4.24 (2.56%)
Ex-Dividend DateAug 23, 2021
1y Target Est187.17
  • Insider Monkey

    11 Best Dividend Stocks To Buy According To Warren Buffett

    In this article, we discuss the 11 best dividend stocks to buy according to Warren Buffett. You can skip our detailed analysis of Buffett’s hedge fund and his investment philosophy and go directly to read the 5 Best Dividend Stocks To Buy According To Warren Buffett. Warren Buffett is an American businessman, investor, and CEO […]

  • Motley Fool

    Can AstraZeneca's COVID Antibody Therapy Win Against Regeneron and Eli Lilly?

    AstraZeneca (NASDAQ: AZN) awaits U.S. Emergency Use Authorization for its COVID-19 antibody therapy as a prophylaxis. In this Motley Fool Live video recorded on Oct. 13, Motley Fool contributors Keith Speights and Brian Orelli discuss how effective AstraZeneca might be in competing against antibody therapies marketed by COVID-19 antibody therapies already on the market.

  • Motley Fool

    2 Upcoming FDA Approval Decisions That Investors Should Really Watch

    In this Motley Fool Live video recorded on Oct. 13, Fool contributors Keith Speights and Brian Orelli discuss two upcoming U.S. Food and Drug Administration (FDA) approval decisions that investors should keep an eye on. Keith Speights: Brian, on another note, the FDA is set to make several important approval decisions in the fourth quarter. Brian Orelli: Biomarin (NASDAQ: BMRN) has one coming up on Nov. 20.

Advertisement
Advertisement